Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer, early

2611 - A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation


08 Oct 2016


Breast cancer, early


Jennifer Litton


Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364


J.K. Litton1, M. Scoggins2, D.L. Ramirez1, R.K. Murthy1, G.J. Whitman2, K.R. Hess3, B.E. Adrada2, S.L. Moulder1, C.H. Barcenas1, V. Valero1, D. Booser1, J. Schwartz Gomez1, G.B. Mills4, H. Piwnica-Worms5, B.K. Arun1

Author affiliations

  • 1 Breast Medical Oncology, MD Anderson Cancer Center, 77030 - Houston/US
  • 2 Diagnostic Radiology, MD Anderson Cancer Center, 77030 - Houston/US
  • 3 Biostatistics, MD Anderson Cancer Center, 77030 - Houston/US
  • 4 Systems Biology, MD Anderson Cancer Center, 77030 - Houston/US
  • 5 Vice Provost Of Science, MD Anderson Cancer Center, 77030 - Houston/US


Abstract 2611


Single agent PARP inhibitors have not been evaluated in untreated BRCA mutation carriers with early stage breast cancer. Concerns over efficacy and delay of initiation of chemotherapy may inhibit accrual in the neoadjuvant setting. In this pilot study, we evaluated if patients (pts) would accrue to a non-chemotherapy as their first treatment and if the toxicity profile would be acceptable.


The study was approved by the Institutional Review Board. Eligibility included > 1 cm tumor and germline BRCA mutation. HER2+ tumors were excluded. Pts underwent a pre-treatment biopsy, 2 months of talazoparib, off-study core biopsy, anthracycline and taxane-based chemotherapy +/-carboplatin, followed by surgery. Ultrasound tumor evaluations by dedicated breast ultrasonographers were obtained at baseline, 1 and 2 months. Success was defined if 20 patients could be accrued within 2 years and 


Thirteen pts (BRCA1 + =10; BRCA2 + =3) participated from 08/2015 – 03/2016. Median age was 40 years (25-55). Eight had hormone receptor- and 4 had hormone receptor+ breast cancer, and 1 metaplastic. Two had clinical stage III, 9 had clinical stage II, and 2 had clinical stage I cancers. Decreases in tumor volume occurred in all 13 patients following 2 months of talazoparib monotherapy. The average volume loss was 78% (range 30-98%). Talazoparib was well tolerated with no grade 4 toxicities and only one patient requiring dose reduction due to grade 3 neutropenia. Common toxicities were neutropenia (n = 11), anemia (n = 8), nausea (n = 7), dizziness (n = 8) and fatigue (n = 8), which were grade 1, except: neutropenia (grade 2 = 4; grade 3 = 3) and grade 2 anemia or thrombocytopenia (n = 1 each). To date, pts have had no difficulty with transition to chemotherapy.


Given the profound clinical response with only 2 months of therapy and favorable toxicity profile, this pilot study was discontinued early after 13 pts accrued within 8 months at a single institution and 0 incidences of grade IV toxicity. An expansion cohort to estimate pathologic response to talazoparib alone with 4-6 months is underway.

Clinical trial identification


Legal entity responsible for the study

The University of Texas MD Anderson Cancer Center


MD Anderson Moonshot, Wolff-Toomim Fund. Drug only was provided by Biomarin and then Medivation once the drug was purchased by Medivation


J.K. Litton: I currently have research funding from Medivation, Genentech, Novartis and formerly from Biomarin; as the Principal Investigator of ongoing trials at my institution. No personal compensation.

All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings